Trial Profile
Impact of the Combination of Durvalumab (MEDI4736) Plus Olaparib (AZD2281) Administered Prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2019
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms NEODURVARIB
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 28 May 2018 New trial record